Shire's Vyvanse gets FDA approval as maintenence treatment in adults with ADHD
Shire announced that the FDA approved the prescription medication Vyvanse Capsules as a maintenance treatment for adults with ADHD. The approval is based on results from a randomized withdrawal study designed to evaluate the efficacy of Vyvanse in adults who were receiving treatment with Vyvanse for a minimum of 6 months prior to enrolling in the study. Significantly more patients treated with Vyvanse maintained ADHD symptom control compared with placebo as determined by the proportion of patients who met criteria for relapse of symptoms at end point during the six-week randomized double-blind withdrawal phase of the study. This new approval adds to the indication for Vyvanse as a treatment for ADHD in patients ages 6 and above. :theflyonthewall.com
News For SHPGY From The Last 14 Days
Check below for free stories on SHPGY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
